Cameron Turtle, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A.

faculty member

Cameron Turtle, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A.

Associate Member
Clinical Research Division, Fred Hutch

Anderson Family Endowed Chair for Immunotherapy
Fred Hutch

Fax: 206.667.7983
Mailstop: D3-100

Dr. Cameron Turtle studies how immune T cells can be engineered to fight hematologic malignancies, such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia and acute myeloid leukemia. He is an Associate Member at Fred Hutch and Associate Professor in the Department of Medicine at the University of Washington (UW) in Seattle, WA.  He serves as an attending physician on the Hematopoietic Cell Transplant Service and the Immunotherapy Service at Seattle Cancer Care Alliance, Fred Hutch’s clinical care partner, and the UW Medical Center. His laboratory in the Clinical Research Division at Fred Hutch is focused on understanding the characteristics of distinct subsets of human CD8+ T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after blood stem cell transplantation.

Dr. Turtle’s lab has extensive expertise in the genetic modification and analysis of T cells, and he leads several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies for patients with B-cell malignancies.

Other Appointments & Affiliations

Associate Professor
University of Washington School of Medicine

Attending Physician
Seattle Cancer Care Alliance

Education

M.B.B.S. (Medicine), University of Sydney, Australia; 1993

Fellow of the Royal Australasian College of Physicians (FRACP); 2000

Fellow of the Royal College of Pathologists of Australasia (FRCPA); 2000

Ph.D., University of Queensland, Australia; 2005

Research Interests

Dr. Turtle’s lab takes a bench-to-bedside-to-bench approach to developing cellular immunotherapies for patients with hematologic malignancies. By studying the reasons for success and failure of T cell therapies in patients treated on their clinical trials, the team takes a rational approach to improving treatment of patients with cancer.

spotlight

“Immune effector cell therapy has the potential to create new paradigms for the treatment of people with cancer.”

—Dr. Cameron Turtle

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210